# R-42 — LEO Pharma Finacea Foam — Azelaic acid 15% foam

The only registration programme in this entire register whose subjects had a mean age of 50.6 — which is to say, the only trial population that looks like the people this site is written for. It also happens to be the cheapest prescription in the register.

- **Canonical:** https://www.30plusskin.care/reviews/finacea-foam-azelaic-acid-review
- **Site:** 30+/SKIN — Skincare, published as a spec sheet.
- **Issue:** ISSUE NO. 13 / REV. 2026.10
- **Standing terms:** INDEPENDENT · AFFILIATE-FUNDED · NOT MEDICAL ADVICE

---

## Verdict

- **Stance:** RECOMMENDED — Buy it. The formula, the disclosure and the price all hold up.
- **Weighted score:** 81/100 across 75% of the scoring model
- **Score scope:** See assessed criteria
- **Category:** PRESCRIPTION MANUFACTURED / ROSACEA — PAPULES AND PUSTULES
- **Price:** $36 — PER 50 G CAN · TWICE DAILY
- **Container size:** 50 G
- **Prescription:** yes
- **Compounded:** no
- **Assessment basis:** DESK REVIEW
- **Last updated:** 2026-08-02
- **Manufacturer page:** https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9fabd24e-4c3b-49a0-aa5f-c8d75ae67572

Start with the demographic table, because it is unique here. The two trials enrolled 1,362 subjects aged 19 to 92, mean age 50.6, 73.4% female. Every other registration programme in this register was run in acne populations with a mean age around twenty. This is the one set of trial results that was actually generated in the bodies of the people reading it.

The efficacy is solid rather than spectacular and reported with unusual care. Investigator global assessment success — clear or minimal, with at least a two-step reduction — reached 32.1% and 43.4% against 23.4% and 32.5% on vehicle. Inflammatory lesions fell by 13.2 and 13.3 against 10.3 and 9.5. The gaps are around nine to eleven points; the vehicle arms are high, which for rosacea is normal and which the label makes no attempt to hide.

Azelaic acid does several useful things at once: it normalises keratinisation, it is antimicrobial, it reduces reactive oxygen species, and it interferes with the cathelicidin processing now understood to be central to rosacea. It also inhibits tyrosinase, which is why it turns up in pigmentation formulas across this register — including in compounded rosacea creams at 17%, above this approved strength.

Three practical notes. There have been reports of hypopigmentation after azelaic acid use, and the label instructs monitoring in patients with dark complexions specifically because the drug has not been well studied in them. The propellant is flammable — no smoking or naked flame during or immediately after application. And with a discount card this is available from around $36, which makes it comfortably the best value prescription we have assessed.

## Actives, as published

| Active | Concentration | Role | Benchmark | Assessment | Flagged |
| --- | --- | --- | --- | --- | --- |
| Azelaic acid | 15% | Anti-inflammatory, antimicrobial, normalises keratinisation, reduces reactive oxygen species and cathelicidin processing, inhibits tyrosinase | 15% is the rosacea-approved strength; 20% is approved for acne | The approved strength, in the format it was trialled in. Worth holding beside the compounded rosacea cream at R-33, which uses 17% — above the concentration these trials tested and below the acne strength, at a number nobody has studied for either indication. This is what 15% actually produced, in 1,362 people, over twelve weeks. | no |

## Scoring

| Criterion | Weight | Score | Note |
| --- | --- | --- | --- |
| EVIDENCE FOR THE ACTIVE | 30% | 78/100 | Two vehicle-controlled 12-week trials in 1,362 subjects with a clearly defined five-point IGA, published exclusion criteria and both endpoints reported. Uniquely for this register, the population's mean age was 50.6. Marked down because the treatment effect over vehicle is modest at nine to eleven points and because 95.7% of subjects were Caucasian. |
| FORMULATION INTEGRITY | 20% | 82/100 | A foam vehicle chosen to deliver a well-evidenced acid to inflamed skin with less occlusion and better spread than the gel, at the approved strength, with a published fill weight and excipient list. Marked down for the flammable propellant, which is a genuine practical constraint the label states plainly. |
| DISCLOSURE | 15% | 88/100 | Publishes concentration in per cent and grams per gram, the fill weight, the full IGA definitions, both trials with vehicle arms, the complete exclusion criteria, the trial demographics including age range and mean, the hypopigmentation signal with an instruction to monitor darker complexions, the eye irritation risk and the flammability. Held back only because the hypopigmentation reports are not quantified. |
| TOLERANCE IN USE | 15% | not scorable | Not assessed. Azelaic acid is the most reliably stinging topical in the rosacea category and a foam vehicle is an attempt to soften that. A panel would settle whether it succeeds, which is the single most useful thing anyone could add to this label. |
| TEXTURE & WEAR | 10% | not scorable | Not assessed. A foam is a genuinely different experience from a gel and is the main reason to choose this format over the cheaper one. |
| COST PER APPLICATION | 10% | 76/100 | From around $36 with a discount card against an average retail near $261, with generic azelaic acid 15% widely available and a published fill weight. Twice-daily dosing consumes product faster than a once-daily product, but this is still the cheapest prescription in the register by a wide margin. |

_A criterion that cannot be assessed from published information is not guessed at. Its weight is removed from the denominator, and the coverage figure above says how much of the model survived._

## Strengths

- The only registration programme here whose trial population matches this site's readership: mean age 50.6, range 19 to 92.
- 1,362 subjects across two vehicle-controlled 12-week trials.
- Full IGA scale definitions published, so 'success' is checkable rather than assumed.
- Both trials reported, including the weaker one.
- Complete exclusion criteria published — ocular, phymatous and plaque-type rosacea were all excluded.
- Hypopigmentation signal disclosed with a specific instruction to monitor darker complexions.
- Flammability of the propellant stated plainly.
- Concentration, fill weight and excipients all published.
- Around $36 with a discount card — the cheapest prescription in this register.
- Generic azelaic acid 15% is widely available.
- A mechanism that acts on cathelicidin, which is central to current understanding of rosacea.

## Weaknesses

- Treatment effect over vehicle is modest — roughly nine to eleven points.
- Vehicle arms reached 23.4% and 32.5%, so a third of the apparent benefit is not the drug.
- 95.7% of trial subjects were Caucasian, and the label concedes azelaic acid has not been well studied in dark complexions.
- Hypopigmentation reports are disclosed but not quantified.
- Twice-daily dosing is harder to sustain than once daily and consumes product faster.
- Azelaic acid stings, and no comparative tolerability data against the gel are published.
- Ocular, phymatous and plaque-type rosacea were excluded, so nothing here applies to them.
- The propellant is flammable, which is a real constraint for some households.

## Suits

- Someone with papulopustular rosacea who wants the best value prescription available.
- Someone in their forties, fifties or sixties who wants evidence generated in their own age group.
- Someone who has found azelaic acid gel too heavy or occlusive.
- Someone who needs a treatment that also acts on post-inflammatory pigmentation, given azelaic acid's tyrosinase activity.
- Someone who wants a rosacea option that is neither an antibiotic nor a retinoid.

## Avoid if

- Your rosacea is primarily erythema and telangiectasia — this treats papules and pustules.
- You have ocular, phymatous or plaque-type rosacea, all of which were excluded from these trials.
- You have a darker complexion and are not willing to monitor for hypopigmentation.
- You have stung badly on azelaic acid before, in which case the format change may not be enough.
- You cannot manage twice-daily application reliably.
- You smoke and would apply this near a flame — the label's flammability warning is not decorative.

## The full assessment

### What it is

Azelaic acid 15% in a hydrophilic foam, applied twice daily, approved for the inflammatory papules and pustules of mild to moderate rosacea. Around $36 with a discount card. It is the cheapest prescription in this register and, by trial population, the most relevant.

**RECORD**

| Field | Value |
| --- | --- |
| BRAND | LEO PHARMA |
| PRODUCT | FINACEA (AZELAIC ACID) FOAM, 15% |
| ACTIVE | AZELAIC ACID 15% W/W — 0.15 G PER GRAM |
| APPROVAL | FDA APPROVED — NDA, NOT COMPOUNDED |
| INDICATION | PAPULES AND PUSTULES OF MILD TO MODERATE ROSACEA |
| DOSING | TWICE DAILY |
| TRIAL DURATION | 12 WEEKS · 2 TRIALS · N=1,362 |
| TRIAL MEAN AGE | 50.6 YEARS · RANGE 19–92 |
| PRICE | FROM ~$36 · ~$261 AVERAGE RETAIL |

### The demographic table nobody reads

A total of 1,362 subjects aged 19 to 92 years, mean age 50.6, 95.7% Caucasian, 73.4% female.

> **A TRIAL POPULATION THAT LOOKS LIKE OUR READERS** — The acne programmes behind the retinoids at R-36, R-37 and R-38 had mean ages around twenty, with 42% to 45% of subjects under eighteen. Winlevi at R-39 had a mean age of 19.7. Renova at R-34 excluded anyone over 71. Almost everything a thirty-five- or fifty-year-old is prescribed for their skin was trialled on people half their age, and the extrapolation is so routine that nobody names it. Here the trial was run in the population being treated — because rosacea is a midlife disease and the enrolment followed it. Only two other programmes in this register can say the same, and both for the same reason.

This does not make the drug better. It makes the evidence more directly applicable, which is a different and rarer thing. It is also worth carrying into other conversations: when a service tells you a treatment is proven, a fair follow-up is 'proven in whom'.

### The results, with the vehicle arms in plain sight

**FIG. 1 — IGA SUCCESS AT WEEK 12** — Success required a score of clear or minimal with at least a two-step reduction from baseline. Trial 1: N=483 against 478. Trial 2: N=198 against 203. Note the vehicle arms — a foam base applied twice daily, plus trial participation and trigger avoidance, produced success in a quarter to a third of subjects.

| Item | Value (% SUCCESS) | Note |
| --- | --- | --- |
| FINACEA FOAM — TRIAL 1 | 32.1 | Against 23.4% on vehicle: an 8.7-point gap |
| VEHICLE — TRIAL 1 | 23.4 | The foam base alone |
| FINACEA FOAM — TRIAL 2 | 43.4 | Against 32.5% on vehicle: a 10.9-point gap |
| VEHICLE — TRIAL 2 | 32.5 | The foam base alone |

_Scale maximum: 45% SUCCESS._

Inflammatory lesion counts fell by 13.2 and 13.3 from a mean baseline of 21.3, against 10.3 and 9.5 on vehicle. So the typical trial subject went from about 21 lesions to about 8 on drug, and to about 11 on vehicle.

Those vehicle arms deserve attention rather than embarrassment. Subjects were instructed to avoid the foods, drinks and products that provoked their own flushing, and to stop using soaps, astringents, tinctures and abrasives. A meaningful part of what the vehicle arm achieved was trigger avoidance and the removal of irritants — which is, in fact, treatment. It is simply treatment that costs nothing and that no product page will sell you.

### What the label warns about

**THREE WARNINGS, ALL SPECIFIC**

| Field | Value |
| --- | --- |
| HYPOPIGMENTATION | ISOLATED REPORTS; NOT WELL STUDIED IN DARK COMPLEXIONS; MONITOR |
| EYES AND MUCOSA | AZELAIC ACID IRRITATES THE EYES — AVOID CONTACT |
| FLAMMABILITY | PROPELLANT IS FLAMMABLE — NO FIRE, FLAME OR SMOKING DURING OR AFTER APPLICATION |

The hypopigmentation warning is the substantive one. Azelaic acid inhibits tyrosinase — that is why it works on pigmentation — and the same mechanism can lighten skin that was not meant to be lightened. The label's phrasing is careful: reports exist, the drug has not been well studied in patients with dark complexions, and those patients should be monitored for early signs. Anyone with a darker complexion should hear that sentence from their prescriber rather than discovering it on a label six weeks in.

### Fifteen per cent, and the numbers that are not fifteen

Azelaic acid is approved at 15% for rosacea and 20% for acne. Both figures come from trial programmes. This register has already found it compounded at 17% in a rosacea cream, and at 10% in a compounded anti-ageing formula, and at 6% in a compounded pigment formula.

None of those is wrong in itself. But 15% is the number with 1,362 subjects behind it, and every departure from it is an assumption about a dose-response curve nobody has drawn. That is the whole argument for reading manufactured labels alongside compounded product pages: not because the manufactured product is always better, but because it is the only place the numbers came from.

### If you are considering it

- Ask about generic azelaic acid 15% — same strength, and the price difference is large.
- Twice daily, morning and evening, on cleansed skin.
- Give it twelve weeks. Both trials read out then.
- Do the trigger work the trial subjects were told to do. The vehicle arms show how much of it is worth.
- Stop using soaps, astringents, tinctures and abrasives while you are on it — the trials excluded them for a reason.
- If you have a darker complexion, agree in advance what you are watching for.
- Keep it away from your eyes.
- Do not apply it near a naked flame or while smoking.
- If it stings persistently rather than transiently, say so — the gel and the foam are not identical experiences.

### Where we stand

At 81 this is the best combination of evidence, disclosure and price in the register. It is not the most effective drug here — R-40 does more for inflammatory rosacea on stronger numbers — but it costs a fraction as much, it is trialled in the right population, and it does several useful things at once for skin that is inflamed and pigmenting simultaneously, which describes a great many people over thirty.

The wider point is the one the vehicle arms make. A third of trial subjects improved on foam base and instructions. If you take nothing else from this review, take the instructions: avoid your own triggers, stop the astringents, and give whatever you use twelve weeks before judging it.

**READ ALONGSIDE**

- [R-40 Galderma Soolantra](/reviews/soolantra-ivermectin-cream-review) — RECOMMENDED 82/100 — Stronger numbers for the same lesions, at several times the price.
- [R-33 Alloy Rosacea Face Cream Rx](/reviews/alloy-rosacea-face-cream-review) — CONDITIONAL 70/100 — Azelaic acid compounded at 17% — above the strength trialled here.
- [R-41 Mayne Pharma Rhofade](/reviews/rhofade-oxymetazoline-cream-review) — CAUTION 62/100 — The drug for redness rather than lesions, and what its trials returned.

## Where to buy

| Retailer | Price | Link | Note | Commission-bearing |
| --- | --- | --- | --- | --- |
| Prescriber + retail pharmacy | from ~$36 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9fabd24e-4c3b-49a0-aa5f-c8d75ae67572 | Prescription only. Average retail near $261; discount-card prices start around $36. Generic azelaic acid 15% is widely available. | no |

We earn nothing on this link. This is the cheapest prescription in the register and one of the best evidenced — ask about the generic and about the gel format if foam is awkward for you.

**Also featured:** [CoreAge Rx skincare](https://try.coreagerx.com/skincare?utm_source=30plusskin&utm_medium=affiliate&utm_campaign=review&utm_content=finacea-foam-azelaic-acid-review&utm_term=markdown) — Browse CoreAge Rx's prescription skincare range for concerns including fine lines, dark spots, blemishes and more.

## Sources

- [FDA-approved labelling — FINACEA (azelaic acid) Foam, 15%, LEO Pharma Inc.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9fabd24e-4c3b-49a0-aa5f-c8d75ae67572) — The 15% w/w strength stated as 0.15 g of azelaic acid per gram; the two 12-week vehicle-controlled trials in 1,362 subjects aged 19 to 92 with a mean age of 50.6, 95.7% Caucasian and 73.4% female; the mean baseline lesion count of 21.3; IGA success of 32.1% against 23.4% and 43.4% against 32.5%; mean nominal lesion changes of −13.2 and −13.3 against −10.3 and −9.5; the full IGA scale definitions; the exclusion of ocular, phymatous and plaque-type rosacea; the trigger and irritant avoidance instructions given to subjects; and the hypopigmentation, eye irritation and flammability warnings. Read 2 August 2026.
- [GoodRx — Finacea and azelaic acid pricing](https://www.goodrx.com/finacea) — Discount-card prices starting around $36.43 against an average retail price near $261.45. Retrieved 2 August 2026.

## Related records

- [L-10 Proven in whom](/ledger/proven-in-whom)
- [R-40 Galderma Soolantra](/reviews/soolantra-ivermectin-cream-review) — RECOMMENDED
- [R-33 Alloy Rosacea Face Cream Rx](/reviews/alloy-rosacea-face-cream-review) — CONDITIONAL
- [L-04 The number nobody publishes](/ledger/the-number-nobody-publishes)
- [L-12 Rosacea prescriptions: persistent redness and bumps are different targets](/ledger/rosacea-prescriptions-redness-vs-bumps)
- [R-68 Skin Medicinals Compounded Rosacea Treatment](/reviews/skin-medicinals-rosacea-review) — CONDITIONAL

---

## PROMOTIONAL SPOTLIGHT: Explore CoreAge Rx skincare

More options for your skin. A patient community to connect with along the way.

**Five skincare options to explore** — Browse CoreAge Rx's prescription skincare range for concerns including fine lines, dark spots, blemishes and more.

**Connect with other patients** — Explore the CoreAge Rx patient community for shared experiences, conversations and support beyond your daily routine.

[CHECK OUT COREAGE RX SKINCARE](https://try.coreagerx.com/skincare?utm_source=30plusskin.care&utm_medium=affiliate&utm_campaign=skincare_reviews&utm_content=reading_footer)

[EXPLORE THE PATIENT COMMUNITY](https://community.coreagerx.com/)

[Read our CoreAge Rx reviews](/reviews/coreage-rx-skincare-review)

Prescription options require a clinician's assessment. Compounded medications are not FDA-approved. Community discussions do not replace medical advice.

[Product range](https://help.coreagerx.com/medication/coreage-rx-prescription-skincare) · [Community information](https://www.coreagerx.com/contact-us/)

[About promotional placements](/disclosure)

---

## Elsewhere in the register

- [Review register](/reviews)
- [Active monographs](/actives)
- [Brand register](/brands)
- [Evidence register](/evidence)
- [The ledger](/ledger)
- [How we test](/how-we-test)
- [Agent guide](/llms.txt)
- [Sitemap](/sitemap.xml)

_SOURCE-BASED ASSESSMENTS. PUBLISHER PREFERENCES ARE IDENTIFIED SEPARATELY._